This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Trubion Licenses Drug To Facet In $196.5M Deal

NEW YORK (AP) ¿ Facet Biotech Corp. will pay Trubion Pharmaceuticals Inc. as much as $196.5 million and make a $10 million investment in the company in return for the marketing rights for an experimental leukemia drug, the companies said Friday.

Trubion is running early-stage clinical tests of TRU-016 as a treatment for chronic lymphocytic leukemia. Facet will pay $20 million upfront in the deal and as much as $176.5 million more if the drug advances through clinical development, review by regulators, and reaches sales targets.

Facet will also buy 2.2 million newly issued Trubion shares for $10 million.

The companies will share the costs of developing, selling and marketing the drug. The deal includes the worldwide rights to TRU-016 in diseases other than leukemia, as well as the rights to similar drugs in Trubion's pipeline. Trubion said TRU-016 could treat other cancers that affect the immune system's B-cells, along with autoimmune and inflammatory diseases.

Trubion is a development-stage company and does not have any products on the market. In morning trading, shares of the Seattle-based company skyrocketed $2.26, or 59 percent, to $6.09, and reached an annual high of $6.75.

Shares of Redwood City, Calif.-based Facet declined 72 cents, or 6.4 percent, to $10.57.

Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
AAPL $126.46 0.04%
FB $79.99 -1.50%
GOOG $567.38 -1.40%
TSLA $193.79 -3.40%
YHOO $43.50 -1.50%


DOW 17,833.18 -302.54 -1.67%
S&P 500 2,070.95 -30.09 -1.43%
NASDAQ 4,926.5250 -56.2840 -1.13%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs